Key result
Angiotensin receptor blocker use as a class was not associated with an increased risk of cancer in patients with type 2 diabetes (adjusted OR 0.94; 95% CI 0.80-1.10).
Why the study?
Does ARB use affect the risk of incident cancer in patients with type 2 diabetes mellitus?
Population
21,750 new diabetic patients who started antihypertensive treatment from the Taiwan National Health…
Comparison
Angiotensin receptor blockers as a class, as… vs Non-use of ARBs.
Design
Case-control
Follow-up
Up to 7.5 years (July 2000 to December 2007)
Authors
Loading...
Supports ARB class safety in type 2 diabetes; leaves open agent-specific effects for prospective study.
Case-Control (n=6,385)
Does ARB use affect the risk of incident cancer in patients with type 2 diabetes mellitus?
Odds Ratio: 0.94 (95% CI 0.8–1.1)
Absolute Event Rate: 26% vs 26.3%
ARBs as a class do not increase the overall risk of cancer in patients with type 2 diabetes, though individual agents may have varying associations requiring further investigation.
Chang et al. (2011) conducted a case-control in Type 2 Diabetes Mellitus (n=6,385). Angiotensin receptor blockers (ARBs) vs. Non-use of ARBs was evaluated on Cancer incidence (OR 0.94, 95% CI 0.80-1.10). Angiotensin receptor blocker use as a class was not associated with an increased risk of cancer in patients with type 2 diabetes (adjusted OR 0.94; 95% CI 0.80-1.10).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: